Company intelligence / Profile preview

Telo Genomics Corp.

Toronto, Ontario, Canadatelodx.com ↗

Ownership: Private
Development stage: Other

Overview

The company has developed and validated its TeloViewSMM test for smoldering multiple myeloma in collaboration with Mayo Clinic. They are also developing MRD (minimal residual disease) validation tests for multiple myeloma, with data accepted for presentation at ASCO 2025.

Therapeutic areas: NeurologyOncology
Modalities: Diagnostic and prognostic testsliquid biopsies
Industry: Molecular Diagnostics

Partnerships

Mayo Clinic

Beyond the preview

Go deeper on Telo Genomics Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telo Genomics Corp..

Explore the full profile